Aileron Therapeutics, Inc. announced the expansion of an existing drug discovery collaboration with Roche adding a third target in inflammatory disease to the existing oncology targets.

Cerulean Pharma presented final data from the non-small cell lung cancer Phase 1/2a clinical study of CRLX101 at the AACR-NCI-EORTC conference. The drug was well tolerated at the maximum tolerated dose (MTD) and provided encouraging progression free survival (PFS) times.

Viamet Pharmaceuticals Appoints Former Novartis Executive as Chief Medical Officer.

GlobeImmune and Gilead Announce Hepatitis B License and Collaboration Agreement.

Viamet Pharmaceuticals Initiates Phase 1 Clinical Trials for Best-in-Class Novel Antifungal VT-1161.

HemaQuest Pharmaceuticals, Inc., completed enrollment of a 52-patient randomized, multi-dose Phase 2 study in patients with sickle cell disease, designed to evaluate the safety and tolerability of HQK-1001.

Viamet anti-fungal program was selected for inclusion by the National Institutes of Health program for Therapeutics for Rare and Neglected Diseases (TRND) Program.

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

Sheila Gujrathi, M.D., joins Receptos as Chief Medical Officer from Bristol-Meyers Squibb.

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24MM Series A financing. The investment was co-led by Atlas Venture, Lilly Ventures, and SR One.

FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

GlobeImmune announces safety and immunogenicity data from clinical trials in lung cancer with KRAS mutations and CEA expressing cancers.

Sutro Biopharma, which is developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, announced that a study published in the July issue of Biotechnology and Bioengineering demonstrates that the company’s biochemical protein synthesis technology platform enables fast and high-yield protein synthesis, scale-up, and straightforward purification by producing a fully bioactive, human, cytokine at titers of 700 mg/L in only 10 hours.

Cerulean Pharma Inc. appoints Edward Garmey, M.D. to serve as Chief Medical Officer and Senior Vice President.

HemaQuest Pharmaceuticals, a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease. The study is expected to enroll approximately 50 patients. The primary objective is safety and tolerability of HQK-1001, with several secondary objectives including an increase in fetal hemoglobin production. HemaQuest expects interim results from the study in late 2011 and final results in the first quarter of 2012.

Aileron hires industry veteran Anthony Manning, Ph.D. as Senior Vice President of Research and Preclinical Development.

Cerulean presents Phase 2a interim clinical data that highlight observations of stable disease in advanced non-small cell lung carcinoma (NSCLC) patients.

Prize4Life partnered with InnoCentive to launch the $1M ALS Biomarker Prize with the goal of accelerating the development of a biomarker—an inexpensive and easy-to-use tool that can accurately measure the progression of ALS in patients. An effective biomarker will make clinical trials of ALS drugs cheaper, quicker, and more efficient.

Receptos, Inc., announced today that their highly selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.

Andrew von Eschenbach, M.D., Former FDA Commissioner and Leading Prostate Cancer Expert, Elected to Viamet Pharmaceuticals Board of Directors.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Protagonist Therapeutics, Inc. announced that they have entered into a collaboration to discover novel peptides for potential development by Ironwood. The collaboration capitalizes on Protagonist's proprietary disulfide rich peptide (DRP) technology platform, and provides Ironwood with the opportunity to develop novel peptides and treatments against clinically–validated targets in therapeutic areas with significant unmet medical needs.

Sutro Biopharma enters into a multiyear collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

Receptos announced an exclusive collaboration focused on structure determination and lead generation for a high value G-protein Coupled Receptor (GPCR) target.

Avid acquisition closes.

Sutro Biopharma today announced that it has appointed Trevor Hallam, Ph.D., as Chief Scientific Officer (CSO). Dr. Hallam will lead Sutro's ongoing efforts in the application of the company's proprietary protein biochemical synthesis platform for the research and development of novel and biosuperior therapeutics.

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin-associated diseases, presented encouraging results at the 2010 ASH meeting from its first two clinical trials evaluating its lead product candidate, HQK-1001 in patients with sickle cell disease and beta thalassemia.

Industry veteran will strengthen Receptos’s clinical and commercial expertise in multiple sclerosis and expand activities including the potential to acquire additional focused therapeutic assets.

Eisai and FORMA Therapeutics announced a strategic drug discovery collaboration. Eisai will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai's pipeline and an option for technology transfer of FORMA's cell-based screening platform.

Cylene Pharmaceuticals presents advances in the development of their first-in-class CK2 inhibitor, CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Targets.

GlobeImmune Announces HCV End of Treatment Response in Phase 2b

Cylene Pharmaceuticals announced the initiation of a Phase 1 clinical trial of their first-in-class CK2 inhibitor, CX-4945 in patients with multiple myeloma.

Roche enters $1.1B deal with Aileron on up to five undisclosed targets in oncology, virology, inflammation, metabolism and central nervous system.

Gilead Science and CGI announce the signing of a Definitive Agreement whereby Gilead will acquire CGI.

R&D Spotlight describes Stapeled Peptides as a revolutionary new class fo drugs to address thousands of currently undruggable targets.

Remember the old "suggestion box" that hit up workers or customers for new ideas? That concept has matured in the 21st century. It's now known as crowdsourcing.

Announced today the closing of a $12M Series B financing led by new investor, Aberdare Ventures.

Early data show strong correlation between florbetapir PET imaging and Alzheimer’s disease beta-amyloid pathology

Announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer.

Silence Therapeutics plc (“the Company”) (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference).

Announced that it has closed on a Series B financing that raised a total of $25.5 million.

Announced the closing of a two-tranche $25 million Series A financing.

Hydra Biosciences and Cubist form collaboration to develop novel ion channel drugs for pain management.

Announced today that it has secured $18 million in a Series B financing to accelerate the development of its novel metalloenzyme inhibitors and to advance its Metallophile™ Technology platform.

Kenneth W. Bair, Ph.D., has been appointed as Senior Vice President and Head of Research and Development.

When Aileron announced its $40 million venture round earlier this month, the press zeroed in closely on the four big pharma venture arms that were crowding in to support the developer. The CEO says the company is on to a brand new way to develop therapeutics and there are clearly a lot of major players who want to have a front seat as researchers put a breakthrough theory to the test.

Announced that research published by Hydra Biosciences scientists and collaborators at Yale University for the first time identified the ion channel TRPA1 as playing an essential role in allergic asthma and demonstrated that Hydra’s TRPA1 antagonist HC-030031 effectively treated allergic asthma in mice.

GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on powerful, targeted molecular immunotherapy for the treatment of cancer.